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Objectives: High levels of b-lactamase production can impact treatment with a b-lactam/b-lactamase inhibitor
combination. Goals of this study were to: (i) compare the mRNA and protein levels of CTX-M-15- and CTX-M-14-
producing Escherichia coli from 18 different STs and 10 different phylotypes; (ii) evaluate the mRNA half-lives and
establish a role for chromosomal- and/or plasmid-encoded factors; and (iii) evaluate the zones of inhibition for
piperacillin/tazobactam and ceftolozane/tazobactam.
Methods: Disc diffusion was used to establish zone size. RNA analysis was accomplished using real-time RT–PCR
and CTX-M protein levels were evaluated by immunoblotting. Clinical isolates, transformants and transconju-
gants were used to evaluate mRNA half-lives.
Results: mRNA levels of CTX-M-15 were up to 165-fold higher compared with CTX-M-14. CTX-M-15 protein levels
were 2–48-fold less than their respective transcript levels, while CTX-M-14 protein production was comparable
to the observed transcript levels. Nineteen of 25 E. coli (76%) had extended CTX-M-15 mRNA half-lives of
5–15 min and 16 (100%) CTX-M-14 isolates had mRNA half-lives of ,2–3 min. Transformants had mRNA
half-lives of ,2 min for both CTX-M-type transcripts, while transconjugant mRNA half-lives corresponded to
the half-life of the donor. Ceftolozane/tazobactam zone sizes were ≥19 mm, while piperacillin/tazobactam
zone sizes were ≥17 mm.
Conclusions: CTX-M-15 mRNA and protein production did not correlate. Neither E. coli ST nor phylotype influenced
the variability observed for CTX-M-15 mRNA or protein produced. mRNA half-life is controlled by a plasmid-
encoded factor and may influence mRNA transcript levels, but not protein levels.
Introduction
In Gram-negative bacteria, b-lactamase production is the most
common mechanism identified conferring resistance tob-lactams.1
Development of b-lactamase inhibitors such as clavulanic acid,
sulbactam and tazobactam provides an effective method for
evading this resistance mechanism. These inhibitors have min-
imal antibiotic activity against enteric bacilli when used alone;
however, a synergistic effect is created when administered in
combination with a penicillin or cephalosporin. Currently there
are four penicillin/inhibitor combinations approved for clinical
use in the USA, including ampicillin/sulbactam, amoxicillin/clavu-
lanate, ticarcillin/clavulanate and piperacillin/tazobactam.2
Recently, the FDA approved the use of ceftolozane/tazobactam
for the treatment of complicated urinary tract infections. By irre-
versibly binding to the enzyme, the b-lactamase inhibitor protects
the b-lactam antibiotic from being hydrolysed by the b-lactamase.
Such b-lactamase inhibitor combinations are highly active against
most class A b-lactamases, but are poorly active against classes C
and D, and inactive against class B b-lactamases.2 The clinical effi-
cacy of a b-lactamase inhibitor/b-lactam combination depends on
many factors, including concentration of inhibitor used in the
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formulation, amount of b-lactamase produced by the bacterial cell
and the concentration of antibiotic that enters the periplasmic
space. Emergence of resistance to b-lactam/b-lactamase inhibitor
combinations can severely impact the ability to treat serious
respiratory tract, urinary tract and bloodstream infections.
Therefore, the ratio ofb-lactam/b-lactamase inhibitor used in com-
binations is critical because use of an inappropriate amount of
inhibitor may impact the therapeutic value of the drug.3
CTX-M-producing Escherichia coli are predominately the pan-
demic ST131 clone and frequently cause urinary tract infec-
tions.4,5 The rapid spread of these strains has led to the CTX-M
pandemic.6 Two major genotypes of CTX-M have become
established worldwide, CTX-M-15 and CTX-M-14. These CTX-M
producers have contributed to both hospital- and community-
acquired urinary tract infections.6 – 11 E. coli represents 50% of
infections leading to uroseptic shock in hospitalized patients
and the majority of uroseptic infections in these patients originate
from the community.12,13 b-Lactam/b-lactamase inhibitor com-
binations can be an effective treatment for infections caused by
CTX-M-producing organisms.2,6,10,13,14
Recently, our laboratory has documented elevated levels of
CTX-M-15 mRNA, in comparison with CTX-M-14 mRNA levels, in
E. coli from human urine samples.15 This difference in steady-
state mRNA expression between CTX-M-15 and CTX-M-14
producers was observed from isolates collected from various
geographical locations worldwide indicating that this observation
was not due to a local clonal population of isolates (Table 1).
Steady-state mRNA levels take into account both the rates of
mRNA synthesis and degradation (mRNA half-life).16 Thus, the
observed differences in expression levels between blaCTX-M-14
and blaCTX-M-15 could be due to an extended mRNA half-life for
blaCTX-M-15 transcripts compared with blaCTX-M-14 transcripts. It is
possible that elevated levels of CTX-M-15 transcripts could lead
to elevated levels of CTX-M-15 protein production negating the
effect of b-lactamase inhibitors. The goal of this study was to
compare the mRNA expression and protein levels of CTX-M-14
and CTX-M-15 b-lactamases among clinical E. coli isolates of vary-
ing STs and phylotypes from human urine samples. In addition,
we evaluated the mRNA half-life of these transcripts and the sus-
ceptibility of these clinical isolates to piperacillin/tazobactam in
addition to evaluating the zone of inhibition for ceftolozane/
tazobactam.17
Methods
Bacterial isolates and susceptibility testing
The study population comprised 57 CTX-M-producing E. coli clinical iso-
lates chosen from 18 geographic locations to ensure that the data did
not represent a local point-source clonal outbreak (Table 1). In addition
to harbouring a CTX-M-14 or CTX-M-15 b-lactamase, most isolates
possessed other b-lactamases such as TEM-1-like or OXA-1, as deter-
mined by family-specific PCR.18 Twenty-five CTX-M-15-producing and
16 CTX-M-14-producing E. coli were used to evaluate mRNA half-life. The
donor strains used in conjugation studies included XQ12 (CTX-M-15), XQ35
(CTX-M-15), C15 (CTX-M-15), D14 (CTX-M-14) and XQ10 (CTX-M-14). J53
(sodium azide resistant) E. coli served as the first recipient strain in the con-
jugation strategy and SalLT2 (Salmonella enterica serovar Typhimurium
LT2) was the intermediate recipient. The final recipient strains used for
conjugation included J53 E. coli, K12 MG1655 (WT E. coli) and FHM16
(ST131 E. coli without a CTX-M enzyme). Vectors used for cloning and
construction of transformants included pCRw2.1, pJET1.2/blunt,
pSP-luc+, pUCP26, pACYC184 (chloramphenicol promoter intact),
pMDR009 (chloramphenicol promoter deleted) and pMP220 (Table S1,
available as Supplementary data at JAC Online). Disc diffusion assays
were performed as previously described and piperacillin/tazobactam sus-
ceptibilities were interpreted using CLSI guidelines.19 In addition, zone
sizes were determined for ceftolozane/tazobactam against 129 total iso-
lates. No disc diffusion breakpoints for Enterobacteriaceae are currently
available for ceftolozane/tazobactam; therefore, only zone sizes can be
reported.
Conjugation assays and clinical plasmid isolation
Conjugation studies were performed using a combination of broth and
filter mating. Transconjugants were created to evaluate the possibility
that a factor(s) encoded on the clinical plasmid was influencing the differ-
ential expression of CTX-M-14 and CTX-M-15 mRNA. Donor strains, XQ12
(CTX-M-15), XQ35 (CTX-M-15), C15 (CTX-M-15), D14 (CTX-M-14) and
XQ10 (CTX-M-14) were conjugated with J53 E. coli using brain heart infu-
sion (Difco, Thermo Scientific) broth mating. A donor to recipient ratio of
1:2.5 was used in all conjugation experiments. Transconjugants were
selected on LB agar with sodium azide (NaN3) 100 mg/L and cefotaxime
24 mg/L. J53 transconjugants were mated with SalLT2 and plated on
MacConkey agar with cefotaxime at 24 mg/L. Following transfer into
SalLT2, the CTX-M-harbouring plasmid was moved by filter mating into
MG1655 and FHM16 with transconjugants selected using MacConkey
agar supplemented with 24 mg/L cefotaxime. Plasmid transfer was con-
firmed via agarose gel electrophoresis (data not shown).20
Cloning and sequencing
Transformants were constructed by amplifying the blaCTX-M-14 and
blaCTX-M-15 structural genes and promoter regions by PCR, ligation of the
PCR products into vector MDR009 (chloramphenicol promoter removed)
and transformation into MG1655, J53 and FHM16 E. coli. The structural
genes encoding CTX-M-14 and CTX-M-15 were sequenced from various
clinical isolates along with their upstream promoter regions using primers
listed in Table S2. All clones and subclones were sequenced. To create the
CTX-M MG1655 transformants, pMRD009 was the final destination vector.
For the luciferase clones, the CTX-M promoter regions were fused to the
luciferase gene and cloned into vector pMP220, while CTX-M genes driven
by the chloramphenicol or lacZ promoter were cloned into pACYC184
(ATCC) and pUCP26, respectively.
Primer efficiency evaluations and determination
of copy number using PCR
Because different primer sets were used for expression of CTX-M-14 and
CTX-M-15, comparisons of the data obtained using these primers could
not be made unless the primers amplified with the same efficiency.
Total DNA was extracted using the Qiagen DNeasyw Blood and Tissue kit.
Ten-fold serial dilutions were prepared ranging from 250 ng to 0.025 ng.
The master mix included 1× Rotor-Gene SYBR Green buffer (Qiagen,
Valencia, CA, USA), 10 pmol of each forward and reverse CTX-M-specific
real-time primer and RNase-free H2O for a total reaction volume of
40.5 mL. A separate master mix was prepared using the endogenous con-
trol primer set (frr or 16S rRNA) and these genes were used to normalize
the expression data. A standard curve was constructed for both the CTX-M
and endogenous control primer sets for each isolate. The Ct values were
plotted against the logarithm of the DNA concentration. Each standard
curve was generated from a linear regression of the plotted points. Using
the slope of each standard curve, the PCR amplification efficiency (E)
was calculated using the equation E¼1021/slope–1,21 while the efficiency
percentage was calculated using the equation E¼ (1021/slope –1)×100.
The R2 value ranged from 0.97 to 0.99. The target [CTX-M-15, CTX-M-14
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Table 1. Characteristics, expression data and susceptibility data (zone sizes in mm) for CTX-M-15- and CTX-M-14-producing E. coli isolates used in
this study
Strain
Geographical location
of isolation blaCTX-M allele ST Phylotype
Relative fold change
in expression+SD
Relative fold
change in
protein+SD
Zone diameter (mm)
piperacillin/
tazobactam
ceftolozane/
tazobactam
D14 Omaha, NE CTX-M-14 ST405 D2 1 1+0.15 22 21
CUMC 247 Omaha, NE CTX-M-15 ST131 B2 72+12.56 2.5+0.39 23 21
XQ12 Seattle, WA CTX-M-15 ST131 B2 21+5.12 10.3+3.6 22 22
XQ35 Seattle, WA CTX-M-15 ST131 B2 8+0.87 1.06+0.87 20 25
A15 Omaha, NE CTX-M-15 ST44 D2 15+1.28 ND
C15 Omaha, NE CTX-M-15 ST405 B1 48+0.70 3.9+2 23 22
H15 Omaha, NE CTX-M-15 ST205 B2 20+0.68 12.2+5.0 17 23
W15 Omaha, NE CTX-M-15 ST131 B2 29+1.43 2.6+0.25 17 21
FHM6 India CTX-M-15 ST131 B2 48+8.41 3.2+1.21 21 19
RS059 UK CTX-M-15 ST131 B2 77+32.47 10.0+2.43 23 20
RS061 UK CTX-M-15 ST131 B2 52+3.65 7.7+2.33 24 20
RS007 UK CTX-M-15 ST131 B2 1+0.09 ND
RS120 UK CTX-M-15 ST131 B2 1+0.14 ND
F010 UK CTX-M-15 ST69 D1 26+2.51 3.5+1.5 20 25
F024 UK CTX-M-15 ST2076 D1 46+2.30 ND
F076 UK CTX-M-15 ST182 D1 74+6.92 ND
RS135 UK CTX-M-15 ST131 B2 165+27.76 22.32+10.7 18 20
RS153 UK CTX-M-15 ST617 A2 37+2.75 8.1+1.27 25 30
CMB106 Minneapolis, MN CTX-M-15 ST131 B2 51+8.17 2.1+0.46
JJ2052 S Evanston, IL CTX-M-15 ST90 B1 32+1.58 2.5+1.97
JJ2052 F Evanston, IL CTX-M-15 ST90 B1 32+3.90 2.4+1.80
JJ2053 Evanston, IL CTX-M-15 ST131 B2 214+0.04a UD
JJ2131 Minneapolis, MN CTX-M-15 ST167 A2 47+10.83 2.9+1.79
JJ2235 S Houston, TX CTX-M-15 ST167 A2 39+11.27 15.4+2.75
JJ2235 F Houston, TX CTX-M-15 ST167 A2 62+17.32 4.4+2.41
JJ2236 New York, NY CTX-M-15 ST648 D2 65+10.88 14.1+4.86
JJ2241 New Brunswick, NJ CTX-M-15 ST131 B2 14+3.97 22+0.10a
JJ2242 Rochester, NY CTX-M-15 ST131 B2 6+0.44 UD
JJ2243 Milwaukee, WI CTX-M-15 ST131 B2 1+0.90 UD
JJ2244 Detroit, MI CTX-M-15 ST131 B2 29+4.22 1.7+0.62
JJ2246 S Ewa Beach, HI CTX-M-15 ST410 A2 60+15.83 5.1+1.50
JJ2246 F Ewa Beach, HI CTX-M-15 ST410 A2 155+41.89 28.1+2.48 20 22
JJ2247 Galveston, TX CTX-M-15 ST131 B2 48+7.02 21.3+0.42a 20 22
JJ2251 New York, NY CTX-M-15 ST131 B2 49+5.06 1.6+0.93 20 26
JJ2253 SW Minneapolis, MN CTX-M-15 ST410 A2 36+5.94 2.4+0.57
JJ2253 RG Minneapolis, MN CTX-M-15 ST410 A2 34+5.91 12.1+3.10
JJ2267 Salt Lake City, UT CTX-M-15 ST648 D2 42+25.83 9.5+1.50
JJ2431 New York, NY CTX-M-15 ST131-like B2 39+9.42 23.8+3.15
MHHBS4 Spain CTX-M-15 ST131 B2 49+2.40 6.2+2.10
MHVlab2 France CTX-M-15 ST131 B2 59+15.05 16.1+3.49
QU015 Queensland, Australia CTX-M-15 ST131 B2 14+3.85 1.9+0.55
C14 Omaha, NE CTX-M-14 ST648 D2 5+2.08 5.0+0.82 21 21
La14 Omaha, NE CTX-M-14 ST648 D2 4+1.68 6.2+0.10 26 28
Lo14 Omaha, NE CTX-M-14 ST405 D2 5+0.39 3.1+.81
N14 Omaha, NE CTX-M-14 ST3856 A2 3+0.40 6.2+3.3
F044 UK CTX-M-14 ST131 B2 1+0.15 21.4+0.09a 25 24
NL217 UK CTX-M-14 ST131 B2 1+0.19 1.6+0.75 26 23
XQ10 Seattle, WA CTX-M-14 ST38 D 1+0.40 ND
XQ13 Seattle, WA CTX-M-14 ST68 D 2+0.72 1.5+0.90 23 21
XQ22 Seattle, WA CTX-M-14 ST156 B2 1+0.73 ND 23 23
Continued
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or luciferase (luc)] and reference (frr, 16S rRNA) primer sets did not vary
more than 10% from each other.
blaCTX-M-15 and blaCTX-M-14 relative copy number
determination
Relative gene copy number quantification was calculated using the equa-
tion of Skulj et al.:22 copy number¼ (Ec average) Ctc/(Ep average) Ctp, where
E is the primer efficiency, c is the normalization gene and p is the gene of
interest. Copy number studies were completed on select CTX-M-14- and
CTX-M-15-producing clinical isolates in Tables 2 and 3.
MLST and phylotyping
Seven-locus MLST was done according to the Achtman system (http://
mlst.ucc.ie/mlst/dbs/Ecoli). Major E. coli phylogenetic groups (A, B1, B2
or D) were determined using an established triplex PCR method.23
RNA isolation and mRNA expression assays
RNA was isolated using TRIzolw MaxTM (Invitrogen) from 1.5 mL of mid-
logarithmic phase culture grown in Mueller–Hinton broth (OD600 of
0.5).24 Genomic DNA was removed by RQ1 DNase (Promega, Madison,
WI, USA) treatment. 250 ng of DNA-free RNA was used in 50 mL PCRs
that consisted of the 1× concentration of QuantiTectw SYBRw Green RT–
PCR master mix, RT mix (Qiagen, Hilden, Germany) and 25 pmol of each
primer. RT –PCR was performed on the Rotor Gene Q 5plex high reso-
lution melt system (Qiagen, Valencia, CA, USA) that included RT activa-
tion at 508C for 40 min, HotStart Taq DNA polymerase activation at 958C
for 15 min and three step cycling conditions for 40 cycles. Cycling para-
meters included denaturation at 958C for 30 s, annealing at 518C for
30 s and extension at 728C for 30 s. Relative mRNA expression for
CTX-M-14 and CTX-M-15 was calculated using the 22DDCt method
with D14 as the comparator.24,25 The single copy gene, frr was used
to normalize the data. Three independent RNA isolations and three indi-
vidual RT – PCR assays were completed with a coefficient of variation
of ,10%.
Evaluation of mRNA half-lives
Cultures were grown to mid-logarithmic phase (OD600 of0.5) in Mueller–
Hinton broth and treated with 200 mg/L rifampicin (Sigma Aldrich, St
Louis, MO, USA). Cells were harvested by centrifugation at 0, 2, 4, 6, 8,
10, 15, 20, 25 and 30 min post-rifampicin addition and RNA was isolated
using TRIzolw MaxTM. Real-time RT–PCRs were done using 250 ng of
DNA-free RNA. Data were normalized to the 16S rRNA gene of E. coli.
The equation by Pfaffl26 was used to determine the ratio of transcript
that remained at each timepoint.
Immunoblot for CTX-M-14/CTX-M-15 detection
The linear response range of the Stain-Free fluorescence and the anti-CTX-M
antibody for bacterial lysates was determined by performing a western blot
on a dilution series of total protein ranging from 40 to 0.625 mg as previously
described.27 The protein linearity ranged from 5 to 40 mg (Figure S1) and the
linear range of the anti-CTX-M antibody was from 2.5 to 40 mg (Figure S2).
Therefore, 10 mg of total protein and an antibody dilution factor of 1:45000
were used for immunoblot analyses.
Whole cell protein lysate was prepared from clinical isolates listed in
Table 1 as previously described.28 Stain-Free SDS-PAGE, imaging and total
protein normalization were carried out as previously described.27 A custom
polyclonal antibody specific for CTX-M-14 and CTX-M-15, directed toward
the peptide sequence CAIPGDPRDTT was generated by GenScript
(Piscataway, NJ, USA) and the secondary antibody (horseradish peroxidase-
goat anti-rabbit IgG) was used with a dilution factor of 1:50000. The chemi-
luminescent signal intensity of CTX-M was normalized to the Stain-Free
fluorescent signal intensity of total protein for each isolate. K12 MG1655
(WT E. coli) and FHM16 (clinical isolate without CTX-M) lysates were used
as controls for cross-reactivity to proteins other than CTX-M. To ensure
that the antibody recognized each protein with the same affinity, E. coli
transformants expressing each CTX-M gene (blaCTX-M-15 and blaCTX-M-14)
from a common plasmid driven by the same promoter element were
used to compare the efficiency of antibody detection (data not shown).
Three biological replicates of each isolate were independently collected
and the means of the normalized data sets were used to calculate the rela-
tive amount of CTX-M production.29 Statistical significance of CTX-M protein
levels between isolates was evaluated using a t-test (double-sided and
paired) performed with GraphPad Prism software, version 4.0.
Results
Relative levels of blaCTX-M-14 and blaCTX-M-15 transcripts
The CTX-M b-lactamases originated from the Kluyvera species, a
group of environmental, non-pathogenic organisms that contain
Table 1. Continued
Strain
Geographical location
of isolation blaCTX-M allele ST Phylotype
Relative fold change
in expression+SD
Relative fold
change in
protein+SD
Zone diameter (mm)
piperacillin/
tazobactam
ceftolozane/
tazobactam
XQ24 Seattle, WA CTX-M-14 ST10 A 1+0.17 ND 22 23
JJ2339 Ewa Beach, HI CTX-M-14 ST38 D2 2+0.64 2.1+0.66
JJ2354 Orange County, CA CTX-M-14 ST354 D1 2+0.76 1.4+0.47
JJ2356 Seattle, WA CTX-M-14 ST46 A1 1+0.26 3.7+1.17
FS-ESBL013 Denmark CTX-M-14 ST10 D2 2+0.53 1.3+0.42
FS-ESBL014 Denmark CTX-M-14 ST38 A2 3+1.55 13.9+4.32
FS-ESBL062 Denmark CTX-M-14 ST10 D1 2+0.47 11+1.06
ND, not determined; UD, undetected.
All transcript levels are relative to D14, which was used as the comparator and set to 1.
Fold changes in protein are normalized values.
aDown-regulation of gene or protein production.
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chromosomally encoded CTX-M b-lactamase genes.30 Therefore,
to evaluate the relative expression of both mRNA and protein
levels among the E. coli CTX-M-producing isolates, an E. coli isolate
(D14) that produced a low amount of CTX-M transcript compared
with the other study isolates was used as the comparator
(Table 1). mRNA analysis of CTX-M-specific transcripts relative to
isolate D14 showed that E. coli isolates expressing CTX-M-15
had mRNA transcript levels that ranged from 14-fold lower to
165-fold higher than the comparator. However, most CTX-M-15
producers (32 of 40; 80%) showed 20–165-fold increases in
blaCTX-M-15 transcripts. When mRNA levels of the CTX-M-14 produ-
cers were compared with each other relative to the comparator
strain, D14, the range in expression among these isolates was
only 5-fold (Table 1). Among all the isolates evaluated, the trend
observed for the elevated expression of CTX-M-15 transcripts and
the lower level of CTX-M-14 transcripts were consistent among
the isolates regardless of the geographic location from which
the isolates were collected.
Relationship between CTX-M mRNA expression and
E. coli ST and phylotype
Various STs and phylotypes were evaluated for CTX-M gene
expression and protein production. No correlation was observed
with respect to specific ST and/or phylotype of E. coli expressing
CTX-M-14 or CTX-M-15 genes (Table 1). For example, strains
RS135 and JJ2053 were both identified as ST131 phylotype B2 iso-
lates. However, RS135 expressed the blaCTX-15 gene 165-fold
higher than the comparator D14 strain whereas strain JJ2053
expressed the blaCTX-15 gene 14-fold less than the comparator.
Twenty-one of 41 isolates were ST131 phylotype B2 with
blaCTX-15 gene expression ranging from a 14-fold decrease to a
165-fold increase in CTX-M-15 mRNA levels relative to the com-
parator strain, D14. Three ST405 isolates were evaluated for
CTX-M gene expression. Two strains expressed CTX-M-14 and
were both phylotype D2. Strain Lo14 expressed the blaCTX-14
Table 2. Upstream region and mRNA half-life of selected strains of
CTX-M-15 and CTX-M-14 producers
Strain blaCTX-M allele Upstream region mRNA half-life (min)
XQ12 CTX-M-15 ISEcp1a 8 or 10c
C15 CTX-M-15 ISEcp1a 5
XQ35 CTX-M-15 ISEcp1a ,2
JJ2053 CTX-M-15 ISEcp1a 9
JJ2241 CTX-M-15 ISEcp1-likeb 8
JJ2242 CTX-M-15 ISEcp1-likeb ,2
JJ2243 CTX-M-15 ISEcp1-likeb 12
JJ2244 CTX-M-15 ISEcp1-likeb 15
JJ2247 CTX-M-15 ISEcp1-likeb 2
JJ2131 CTX-M-15 ISEcp1-likeb ,2
JJ2235 S CTX-M-15 ISEcp1-likeb ,2
JJ2235 F CTX-M-15 ISEcp1-likeb ,2
JJ2236 CTX-M-15 ISEcp1-likeb 10
JJ2253 RG CTX-M-15 ND 11
MHHBS4 CTX-M-15 non-ISEcp1b ,2, 7 or 12c
MHVlab2 CTX-M-15 non-ISEcp1b 9
QU015 CTX-M-15 non-ISEcp1b ,2
JJ2251 CTX-M-15 non-ISEcp1b 9
JJ2052 S CTX-M-15 non-ISEcp1b 2
JJ2052 F CTX-M-15 non-ISEcp1b 9
JJ2246 S CTX-M-15 non-ISEcp1b ,2 or 7c
JJ2246 F CTX-M-15 non-ISEcp1b 7
JJ2267 CTX-M-15 ND 9
JJ2253 SW CTX-M-15 ND 5
JJ2243 CTX-M-15 ND ,2
D14 CTX-M-14 ISEcp1a ,2
XQ10 CTX-M-14 ISEcp1a ,2
C14 CTX-M-14 ISEcp1a ,2
La14 CTX-M-14 ISEcp1a ,2
Lo14 CTX-M-14 ISEcp1a 3
N14 CTX-M-14 ISEcp1a ,2
F044 CTX-M-14 ISEcp1a ,2
XQ22 CTX-M-14 ISEcp1a ,2
XQ24 CTX-M-14 ISEcp1a ,2
FS-ESBL014 CTX-M-14 ND ,2
JJ2339 CTX-M-14 ND ,2
JJ2354 CTX-M-14 ND ,2
JJ2356 CTX-M-14 ND ,2
NL217 CTX-M-14 ND ,2
FS-ESBL013 CTX-M-14 ND 3
FS-ESBL062 CTX-M-14 ND 3
Each mRNA half-life represents one experiment. Studies were not
completed in triplicate due to cost.
Half-life calculated using the 2001 method of Pfaffl.26
aConfirmed by sequence analysis.
bUpstream region PCR mapped.
cIndicates the graph intersects the 50% transcript remaining line at more
than one timepoint.
Table 3. Steady-state mRNA expression and mRNA half-lives for CTX-M-14
and CTX-M-15 transconjugants in different E. coli backgrounds
Clinical isolate donor/
transconjugant
blaCTX-M
allele
Relative mRNA
levels+SD
mRNA
half-life (min)a
XQ12 CTX-M-15 20+5.12 8–10
XQ12-J53 CTX-M-15 23+10.58 7
XQ12-K12 MG1655 CTX-M-15 31+4.41 9
XQ12-FHM16 CTX-M-15 26+3.63 9
XQ35 CTX-M-15 4+1.60 ,2
XQ35-J53 CTX-M-15 7+3.47 ,2
XQ35-K12 MG1655 CTX-M-15 26+7.21 ,2
XQ35-FHM16 CTX-M-15 16+3.12 ,2
C15 CTX-M-15 56+17.52 5
C15-J53 CTX-M-15 62+6.89 5
C15-K12 MG1655 CTX-M-15 25+12.73 5
C15-FHM16 CTX-M-15 59+28.98 5 or 11
D14 CTX-M-14 1+0.20 ,2
D14-J53 CTX-M-14 1+0.46 ,2
XQ10 CTX-M-14 0.73+0.48 ,2
XQ10-J53 CTX-M-14 0.76+0.39 ,2
All fold changes are relative to D14.
aCalculated using the 2001 method of Pfaffl.26
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gene 5-fold higher than the comparator strain, D14. The
CTX-M-15-producing ST405 strain was of phylotype B1 and
expressed blaCTX-M-15 48-fold higher than the comparator, D14.
Four strains were phylotype D1, but were all different STs (ST69,
ST2076, ST183 and ST354). ST354 expressed the blaCTX-M-14
gene only 2-fold higher than the blaCTX-14 mRNA expression of
D14, but the blaCTX-M-15 mRNA expression observed in the D1 phy-
lotypes ranged from 26- to 74-fold higher compared with D14.
Determination of CTX-M-14/CTX-M-15 mRNA half-lives
from clinical isolates
The differential expression of mRNA was not attributed to the STor
the phylotype of the organism. Therefore, we wanted to deter-
mine whether the differential expression between these two
types of CTX-M transcripts was occurring at the initiation of tran-
scription or post-transcriptionally due to mRNA stability differ-
ences. The promoter regions of 29 strains encoding CTX-M-14 or
CTX-M-15 were sequenced and most of the strains had identical
upstream sequences that housed the insertion sequence ISEcp1
(Table 2). When PCR mapping data were used to define the pro-
moter, there was no difference in the trends of CTX-M-15 expres-
sion for ISEcp1-like upstream elements versus those strains that
did not generate a specific amplicon for the ISEcp1 element (for
example, strains JJ2236 and JJ2246F; Table 2). Taken together,
these data indicated that transcription initiation was probably
not the cause of the differences observed in the mRNA levels.
mRNA half-life, i.e. the degradation rate of a transcript, can
impact steady-state mRNA levels. Therefore, mRNA half-life stud-
ies were performed. The average half-life of an E. coli transcript is
2–3 min.16 Sixteen CTX-M-14-producing clinical E. coli isolates
were evaluated for mRNA half-life. Each isolate had a half-life
of ≤3 min (Table 2 and Figures S3–S7). However, 16 of 25
CTX-M-15-producing E. coli isolates had an extended half-life
of between 5 and 15 min. The remaining nine CTX-M-15 clinical
E. coli isolates had mRNA half-lives of ≤2 min. The difference in
mRNA half-life observed for these isolates could be the result of
chromosomal- or plasmid-encoded factors.
Factors controlling CTX-M mRNA half-life: chromosomal
or plasmid encoded
To determine the contribution of chromosomal- or plasmid-
encoded factors to the observed differences in the half-lives of
the blaCTX-M transcripts, candidate strains were chosen and trans-
conjugants and transformants constructed (Table 3). DNA from
isolates D14 and XQ12 were used as a template to construct
the transformants. For the CTX-M-15-producing isolates, three
clinical isolates representing three distinct mRNA half-lives were
selected to be conjugation donors and included XQ12 (half-life
of 8 –10 min), XQ35 (half-life of ,2 min) and C15 (half-life of
5 min). Three different recipient strains were used for the conjuga-
tions for the CTX-M-15-containing plasmid: J53, MG1655 and
FHM16 (Table 3). For the CTX-M-14-producing isolates, two clinical
isolates both having an mRNA half-life of ,2 min were selected
for conjugation studies and included D14 and XQ10.
Before the half-lives of the CTX-M transconjugant transcripts
were determined, the gene copy number and CTX-M steady-state
expression were evaluated. CTX-M gene copy number was deter-
mined for the D14, XQ10 and XQ12 transconjugants. The copy
number of the CTX-M genes for the transconjugants tested was
identical to the gene copy number determined for the clinical
donor strains, which was 1. D14 was used as the comparator
strain when evaluating steady-state expression of the transconju-
gants to remain consistent with the initial expression data
(Table 3). For most of the transconjugants, the mRNA expression
levels were similar to those of the clinical isolate from which they
were created (Table 3). Compared with D14, CTX-M-15 mRNA
expression in the XQ12 clinical isolate was 20-fold higher and in
the XQ12-J53, XQ12-MG1655 and XQ12-FHM16 transconjugants
was comparable at 23-, 31- and 26-fold higher (Table 3). The
steady-state mRNA expression level for the XQ35 clinical isolate
was 4-fold higher than the comparator strain D14 and expression
in the J53, MG1655 and FHM16 transconjugants was 7-, 26- and
16-fold higher, respectively (Table 3). Interestingly, the mRNA
expression level of the XQ35-MG1655 and XQ35-FHM16 transcon-
jugants was2- to 6-fold higher compared with the XQ35 clinical
isolate and the J53 transconjugant. Steady-state mRNA expres-
sion levels for the C15 clinical isolate and its J53, MG1655 and
FHM16 transconjugants were 56-, 62-, 25- and 59-fold higher,
respectively when compared with D14. The CTX-M-15 expression
level from the C15-MG1655 transconjugant was 2–3-fold lower
compared with the J53 and FHM16 transconjugants (Table 3).
The CTX-M-14 steady-state mRNA levels for XQ10 and D14 and
their J53 transconjugants were both similar to those of the D14
clinical isolate (Table 3).
Variation in steady-state levels of mRNA expression was
observed between some of the CTX-M transconjugants, but not
all, when compared with the clinical isolate. These differences
were not due to gene copy number (all isolates had one copy of
the gene), but could be attributed to transcription initiation events
or transcript half-life in these different genetic backgrounds. To
test the influence of these genetic backgrounds on mRNA stability,
the mRNA half-life of each of the transcripts expressed in the
transconjugants was measured (Table 3 and Figures S3 –S7).
Despite the difference in genetic background (J53 versus
MG1655 versus ST131), each of the transconjugant’s mRNA half-
lives reflected the mRNA half-life of the clinical isolate from which
the plasmid was obtained. Specifically, for transconjugant XQ12
the CTX-M-15 transcript had an extended half-life of 7–9 min,
the XQ35 transconjugant had a blaCTX-M-15 mRNA half-life of
,2 min and the C15 transconjugant had a blaCTX-M-15 half-life of
5 min (Table 3). The same trend was seen with the CTX-M-14
transconjugants, each of which had a blaCTX-M-14 half-life of
,2 min, similar to the parent strain. These data indicated that
plasmid-encoded factors and not chromosomally encoded fac-
tors were contributing to the difference in mRNA half-life observed
between blaCTX-M-14 and blaCTX-M-15.
To verify further that a clinical plasmid-encoded factor(s) was
responsible for mRNA stability, the mRNA half-lives of the
CTX-M-14 and CTX-M-15 K12 transformants were evaluated. To
create these constructs, the structural CTX-M-14 or CTX-M-15
gene and upstream promoter regions were amplified, cloned
into pMDR009 and transformed into K12 MG1655 or FHM16
(ST131).31 When mRNA half-lives were evaluated in the MG1655
transformants, both the CTX-M-14 and CTX-M-15 transcripts were
,2 min (Figure S7). To determine whether the ST131 genetic
background would influence the CTX-M-15 transcript half-life,
the mRNA was evaluated in the transformant of ST131 E. coli
strain, FHM16. The mRNA half-life of the CTX-M-15 transcript in
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this transformant was also ,2 min (Figure S7). These data sub-
stantiated that a plasmid-encoded factor(s), rather than the
chromosomal background was responsible for the extended half-
lives of the CTX-M-15 transcripts.
To rule out any contribution of the CTX-M native promoters or
the structural genes themselves on CTX-M half-life, the half-lives
of CTX-M promoter/luciferase fusions, lacZ promoter/CTX-M clones
and chloramphenicol promoter/CTX-M clones were evaluated.
When the promoter regions of the CTX-M-14 and CTX-M-15
genes were fused to luciferase, the half-life of the luciferase
gene was ,2 min for all clones (data not shown). Furthermore,
the half-lives of the CTX-M-14 and CTX-M-15 transcripts driven
by heterologous promoters (lacZ or chloramphenicol) were
,2 min (data not shown). All clones discussed above included
either the CTX-M promoter or structural gene, which had been
removed from its native clinical plasmid and transformed into a
K12 E. coli host.
Relative levels of CTX-M-14 and CTX-M-15 protein
The elevated levels of the CTX-M-15 mRNA transcripts suggested
that the level of CTX-M-15 enzyme produced by those E. coli iso-
lates would also be elevated, perhaps jeopardizing the effective-
ness of b-lactam/b-lactamase inhibitor combinations. Therefore,
western blots were used to evaluate the relative level of CTX-M
b-lactamase produced by the study isolates listed in Table 1.
An 1:1 relationship between mRNA and protein production
was observed for the CTX-M-14-producing isolates (Table 1 and
Figure 1a and b). For example, E. coli isolate C14 expressed both
its CTX-M-14 mRNA and protein at levels 5 times higher than
the comparator isolate, D14. This trend in mRNA and protein
production was seen with all of the CTX-M-14-producing isolates
with levels ranging between 1- and 6-fold higher compared with
isolate D14 (Table 1). In contrast, this direct relationship was not
observed for CTX-M-15-producing isolates. While mRNA levels for
the CTX-M-15 transcript ranged from 14-fold lower to 165-fold
higher than the CTX-M-14 mRNA levels of isolate D14, the corre-
sponding protein levels ranged from undetected to 10-fold higher
(Table 1 and Figure 1a and b). In addition, the higher levels of
CTX-M-15 mRNA did not always correlate with the highest levels
of CTX-M-15 protein production. For example, isolate RS153 had
an mRNA level 37-fold higher than the comparator strain, D14,
but its protein level was only 8-fold higher. While a 77-fold
increase in mRNA levels for strain RS059 was observed, only a
10-fold increase in protein production was noted. Isolate C15
had a 48-fold increase in mRNA compared with only a 2-fold
increase in protein. Moreover, isolates JJ2246F and RS135 had
the most pronounced increases for both mRNA and protein pro-
duction of CTX-M-15 with a 155-fold and 165-fold increase in
mRNA and a 28-fold and 22-fold increase in protein, respectively.
Susceptibility to b-lactam/b-lactamase inhibitor
combinations
Protein production among the test isolates ranged from no
detectable level of protein observed to a 28-fold increase in pro-
tein production for strain JJ2246F. The level of b-lactamase pro-
duction is a key contributor to the b-lactam-resistant phenotype.
Therefore given the range of CTX-M production in these isolates a
subset of 23 isolates were tested to determine the impact CTX-M
b-lactamase production had on piperacillin/tazobactam and
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Figure 1. (a) Immunoblots for CTX-M-14 and CTX-M-15 from 15 representative clinical isolates. Protein levels were compared and analysed relative to
E. coli strain D14. Lane 1, D14 (CTX-M-14); lane 2, CUMC 247 (CTX-M-15); lane 3, W15 (CTX-M 15); lane 4, C15 (CTX-M-15); lane 5, FHM6 (CTX-M-15); lane 6,
XQ12 (CTX-M-15); lane 7, RS059 (CTX-M-15); lane 8, C14 (CTX-M-14); lane 9, NL217 (CTX-M-14); lane 10, F044 (CTX-M-14); lane 11, XQ13 (CTX-M-14; lane
12, H15 (CTX-M-15); lane 13, RS061 (CTX-M-15); lane 14, RS153 (CTX-M-15); lane 15, La14 (CTX-M-14). (b) Relative fold changes in CTX-M-15 and
CTX-M-14 protein from the 15 isolates from (a) normalized to total protein using Stain-Free technology. All protein levels are relative to D14.
Statistical significance of the isolates relative to D14 was evaluated using a t-test (two-tailed and paired) performed with GraphPad Prism 6.0.
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ceftolozane/tazobactam zone size. Disc diffusion breakpoints for
ceftolozane/tazobactam are currently set by the FDA and
available for only Pseudomonas aeruginosa; therefore, susceptibil-
ity data for this drug combination for E. coli could not be deter-
mined. Only zone size comparisons could be made. In spite of
the high-level expression from the CTX-M-15 gene, 7 of 15 isolates
were susceptible to the piperacillin/tazobactam. Isolates W15
and H15 were resistant to piperacillin/tazobactam, while the
remaining isolates were intermediate (Table 1). All of the
CTX-M-14-producing isolates listed in Table 1 were susceptible
to piperacillin/tazobactam. With respect to ceftolozane/tazobac-
tam, all the isolates listed in Table 1 regardless of the level of
protein production observed had zone sizes of ≥19 mm. An
additional 126 isolates not evaluated for protein production, but
possessing either CTX-M-14 or CTX-M-15 b-lactamases, were
also tested against ceftolozane/tazobactam. All 50 of the
CTX-M-14-like-producing isolates had zone diameters for ceftolo-
zane/tazobactam of ≥21 mm. Of the 76 additional isolates pro-
ducing CTX-M-15-like enzymes, 73 showed zone diameters to
ceftolozane/tazobactam of ≥19 mm, while 2 of 76 isolates had
zone diameters of 18 mm and 1 of 76 had a zone diameter
of 14 mm.
Discussion
Previous studies evaluating the effectiveness of ceftolozane/
tazobactam against isolates that produced CTX-M-14 or CTX-
M-15 indicated that the concentration of tazobactam may play
a role in the overall efficacy of this combination when used against
these ESBL-producing bacteria.32,33 When a breakpoint of 1 mg/L
of ceftolozane plus 4 mg/L of tazobactam was used, 12% of
isolates evaluated by Titelman et al.33 were non-susceptible. A
similar finding for ESBL-producing Enterobacteriaceae and cefto-
lozane/tazobactam has been reported by Livermore et al.32 It is
possible that the level of CTX-M production was responsible for
the lack of susceptibility to ceftolozane/tazobactam in these iso-
lates. Given our observation that CTX-M-15 isolates in general
transcribed more mRNA than CTX-M-14 isolates, we wanted to
evaluate the impact that this discrepancy in mRNA expression
would have on CTX-M protein production and ultimately suscepti-
bility to b-lactam/b-lactamase inhibitor combinations. To our sur-
prise, the level of CTX-M protein production for most of the isolates
evaluated was similar for CTX-M-15 and CTX-M-14 producers des-
pite the differences in mRNA expression. Therefore, the level of
CTX-M production was most likely not responsible for the resist-
ance observed in the 12% of isolates evaluated by Titelman.33
The choice of breakpoint for ESBL-producing bacteria is controver-
sial34 and EUCAST and CLSI have set lower breakpoints for
oxyimino-cephalosporins to increase the probability of classifying
isolates as non-susceptible. Our data show that the variation in
susceptibility in ESBL producers for ceftolozane/tazobactam is
not due to levels of b-lactamase production, so this criterion for
establishing breakpoints maybe an oversimplification.
The evaluation of the CTX-M-14 and CTX-M-15 mRNA half-lives
indicated that the prolonged CTX-M-15 half-life observed for
many of the CTX-M-15 producers was controlled by a factor
encoded on the CTX-M-15-harbouring plasmid(s). This conclusion
is substantiated by several experiments. First, transconjugants
from CTX-M-14- or 15-producing donor strains had mRNA half-
lives equivalent to the corresponding donor strains (Table 3).
Second, transformants of cloned CTX-M-14 and CTX-M-15 genes
into identical plasmid vectors had blaCTX-M mRNA half-lives
of ,2 min regardless of the genetic background, including a
ST131 E. coli (FHM16). Third, native or heterologous promoters
expressing blaCTX-M alleles did not influence the mRNA half-
life. These data also indicated that the plasmid backbones of
CTX-M-15-encoding isolates were not identical since some of
these isolates had mRNA half-lives of ≤2 min, whereas others
had half-lives of ≥5 min. We speculate that the CTX-M-15-encoding
plasmids that exhibited shorter half-lives have a similar compos-
ition to the CTX-M-14-encoding plasmids with respect to the
encoded factor that determines mRNA half-life.
Steady-state levels of mRNA expression in the transconjugants
indicated that for two of the three CTX-M-15-producing isolates
(XQ12 and C15) evaluated, the genetic background did not
influence promoter usage, plasmid copy number or transcript
half-life. However, the steady-state level of mRNA for the CTX-
M-15-producing XQ35 transconjugants in the FHM16 and MG1655
backgrounds was 4–6.5-fold higher compared with blaCTX-M-15
expression in the XQ35 clinical isolate. It is possible that when
blaCTX-M-15 was expressed in the FHM16 and K12 MG1655 back-
grounds, the copy number of the plasmid or transcription initiation
events were altered compared with expression in the XQ35 and J53
backgrounds. Copy number has been shown to change even when
the same plasmid vector is used, but transformed into different
hosts (genetic backgrounds) of Enterobacteriaceae.35
Sequence analysis of CTX-M-14/CTX-M-15-containing plasmids
has shown multiple open reading frames of hypothetical proteins
that could encode for a factor that influences the CTX-M transcript
half-life.36 – 38 A protein that can modify mRNA half-life and is
encoded by a plasmid has multiple implications. This factor
could not only prolong the half-life of antibiotic resistance gene
transcripts, as demonstrated in this study, but also influence the
production of factors responsible for virulence or metabolic path-
ways, leading to increased fitness for strains that carry blaCTX-M-15.
Identification of this factor should be a priority, since it could serve
as a potential target for the development of new antimicrobial
agents to limit the production of proteins benefiting from a pro-
longed mRNA half-life.
The ability to evaluate b-lactamases in clinical isolates
using hydrolysis data is difficult for isolates that carry multiple
b-lactamases as in the ones evaluated in this study. Therefore,
to evaluate the level of protein production of CTX-M b-lactamases
only, immunoblot analysis was used. The use of an internal con-
trol to normalize the data is difficult using clinical isolates, as
expression of any internal housekeeping protein may fluctuate
in response to various selective pressures faced by a given organ-
ism. Therefore, the use of Stain-Free technology allows for a more
accurate comparison of relative amounts of protein among clin-
ical isolates.29
The difference observed between the levels of CTX-M-15 mRNA
and protein suggests that these isolates are inefficient in translat-
ing all the transcribed mRNA into functional b-lactamase.
Although some of the mRNA is translated, as evident from
the immunoblot data, the level of CTX-M-15 b-lactamase did
not result in decreased zone sizes to either tested inhibitor com-
bination. This suggests that the rate of penetration of antibiotics
through the outer membrane may be important when evaluating
CTX-M-producing resistant isolates. Even though there are no disc
diffusion breakpoints for Enterobacteriaceae currently available
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for ceftolozane/tazobactam, comparisons between MIC data and
zone size suggest that a zone size of≥19 mm could be considered
susceptible (Cubist data on file). However, those data still contain
some major errors between some isolates regarding MIC versus
disc zone size that need to be resolved (Cubist data on file).
None the less, most of the isolates in this study (126 of 129)
had zone sizes to ceftolozane/tazobactam of ≥19 mm despite
the elevated levels of protein production observed. Notably, iso-
late RS135 produced the highest level of mRNA and the second
highest level of CTX-M-15 protein, yet showed a zone size of
19 mm for ceftolozane/tazobactam. In contrast, the highest pro-
tein production was noted for strain JJ2246F, but the ceftolozane/
tazobactam zone of inhibition was 30 mm indicating that the
level of b-lactamase did not contribute to smaller zone sizes for
these isolates.
It was surprising that the levels of mRNA expression observed
for most CTX-M-15-producing isolates were disproportional to
protein production. This disproportional correlation between
mRNA and protein production could be the result of a translational
block due to an RNA binding protein or small RNA interference, or
the result of decreased CTX-M-15 protein stability compared with
CTX-M-14. The differential levels of expression between mRNA
and protein production did not seem to be influenced by phylo-
genetic background since no correlations could be determined
with ST or phylotype. As the selective pressure increases with
b-lactam/b-lactamase inhibitor combinations or carbapenems,
a future concern is the selection of genomic or plasmidic muta-
tions that will allow increased translatability of the CTX-M tran-
scripts resulting in increased b-lactamase production. These
events could lead to an emergence of CTX-M-producing organ-
isms resistant to b-lactam/b-lactamase inhibitor combinations
and may increase the number of isolates resistant to the carbape-
nems through porin down-regulation. Fortunately, our current find-
ings suggest that resistance in E. coli to b-lactam/b-lactamase
inhibitor combinations including ceftolozane/tazobactam is not
dependent on the type or level of CTX-M b-lactamase produced
by the E. coli isolate, but requires as yet unidentified resistance
mechanisms.
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